Literature DB >> 22539199

Evaluation of the conjoint efficacy in Chinese medicine with the longitudinal latent variable linear mixed model.

Dan-Hui Yi1, Yang Li, Shu-Xin Shao, Yan-Ming Xie, Ya Yuwen.   

Abstract

Chinese medicine (CM) clinical efficacy evaluation research involves the longitudinal multivariate measurement which means that patients are measured repeatedly and each patient is measured by several indicators on each fixed cross-section. Although each indicator can be evaluated separately with a longitudinal linear mixed model, it is important to consider all the endpoints together especially when researchers pay special attention to the change of the conjoint efficacy for several indicators in one patient. In this article, we introduce a latent variable linear mixed model to the CM conjoint efficacy evaluation and discuss why and how to analyze the longitudinal multivariate endpoint data in the clinical CM efficacy evaluation research. It may lead to the new insight of using such methodology in the field of conjoint efficacy evaluating of CM study. And with the definition of syndrome and symptom in the CM theory, the applied discussion brings the insight of CM syndrome evaluating in future. We illustrate this methodology using an example of CM efficacy evaluation from an ischemic stroke research.

Entities:  

Mesh:

Year:  2012        PMID: 22539199     DOI: 10.1007/s11655-012-1095-x

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  8 in total

1.  Latent variable models for longitudinal data with multiple continuous outcomes.

Authors:  J Roy; X Lin
Journal:  Biometrics       Date:  2000-12       Impact factor: 2.571

2.  Design and analysis of group sequential clinical trials with multiple primary endpoints.

Authors:  Michael R Kosorok; Shi Yuanjun; David L DeMets
Journal:  Biometrics       Date:  2004-03       Impact factor: 2.571

3.  Partition testing in dose-response studies with multiple endpoints.

Authors:  Yi Liu; Jason Hsu; Stephen Ruberg
Journal:  Pharm Stat       Date:  2007 Jul-Sep       Impact factor: 1.894

4.  The post-stroke hemiplegic patient. 1. a method for evaluation of physical performance.

Authors:  A R Fugl-Meyer; L Jääskö; I Leyman; S Olsson; S Steglind
Journal:  Scand J Rehabil Med       Date:  1975

5.  Latent variable models with fixed effects.

Authors:  M D Sammel; L M Ryan
Journal:  Biometrics       Date:  1996-06       Impact factor: 2.571

6.  Underlying structure of the National Institutes of Health Stroke Scale: results of a factor analysis. NINDS tPA Stroke Trial Investigators.

Authors:  P Lyden; M Lu; C Jackson; J Marler; R Kothari; T Brott; J Zivin
Journal:  Stroke       Date:  1999-11       Impact factor: 7.914

7.  Post-stroke hemiplegia assessment of physical properties.

Authors:  A R Fugl-Meyer
Journal:  Scand J Rehabil Med Suppl       Date:  1980

8.  Prediction of functional outcome after stroke: comparison of the Orpington Prognostic Scale and the NIH Stroke Scale.

Authors:  S M Lai; P W Duncan; J Keighley
Journal:  Stroke       Date:  1998-09       Impact factor: 7.914

  8 in total
  2 in total

1.  Nao-Xue-Shu Oral Liquid Protects and Improves Secondary Brain Insults of Hypertensive Cerebral Hemorrhage.

Authors:  Hongning Jiang; Ying Qin; Te Liu; Liang Zhang; Mingzhe Wang; Baofeng Qin; Wenfei Jiang; Weilong Liao; Weidong Pan
Journal:  Evid Based Complement Alternat Med       Date:  2016-03-27       Impact factor: 2.629

2.  Nao-Xue-Shu Oral Liquid Improves Aphasia of Mixed Stroke.

Authors:  Yuping Yan; Mingzhe Wang; Liang Zhang; Zhenwei Qiu; Wenfei Jiang; Men Xu; Weidong Pan; Xiangjun Chen
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-19       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.